Document Detail

Integrating predictive biomarkers and classifiers into oncology clinical development programmes.
MedLine Citation:
PMID:  21959287     Owner:  NLM     Status:  In-Data-Review    
The future of drug development in oncology lies in identifying subsets of patients who will benefit from particular therapies, using predictive biomarkers. These technologies offer hope of enhancing the value of cancer medicines and reducing the size, cost and failure rates of clinical trials. However, examples of the failure of predictive biomarkers also exist. In these cases the use of biomarkers increased the costs, complexity and duration of clinical trials, and narrowed the treated population unnecessarily. Here, we present methods to adaptively integrate predictive biomarkers into clinical programmes in a data-driven manner, wherein these biomarkers are emphasized in exact proportion to the evidence supporting their clinical predictive value. The resulting programme demands value from predictive biomarkers and is designed to optimally harvest this value for oncology drug development.
Robert A Beckman; Jason Clark; Cong Chen
Related Documents :
24162227 - Marker-based estimates of identity by descent and alikeness in state among maize inbreds.
1150607 - Inhalation toxicology.
12060827 - A model of the development of the brain as a construct of the thyroid system.
24173787 - Maximum-likelihood models for mapping genetic markers showing segregation distortion. 2...
10783807 - Mixed effects logistic regression models for longitudinal ordinal functional response d...
24163627 - A quasiphysics intelligent model for a long range fast tool servo.
Publication Detail:
Type:  Journal Article     Date:  2011-09-30
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  10     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2011  
Date Detail:
Created Date:  2011-09-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  735-48     Citation Subset:  IM    
Clinical Research Oncology, Daiichi-Sankyo Pharmaceutical Development, 399 Thornall Street, Edison, New Jersey 08837, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ezogabine (retigabine).
Next Document:  The influence of the 'organizational factor' on compound quality in drug discovery.